Cancer antigen 125 (CA125) is a clinical ovarian tumor marker, but its sensitivity is relatively low and other markers are therefore needed to allow discrimination between early ovarian cancer and benign ovarian tumors. This evidence concerns the gene MUC16 and ovarian benign neoplasm.